{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:34:57Z","timestamp":1781199297382,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2668,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1093\/annonc\/mds106","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T05:45:17Z","timestamp":1337147117000},"page":"2065-2071","source":"Crossref","is-referenced-by-count":28,"title":["Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy"],"prefix":"10.1016","volume":"23","author":[{"given":"N.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-J.","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.I.","family":"Khwarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Choung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds106_bb0010","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mds106_bb0015","first-page":"viii225","article-title":"Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II\/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study)","volume":"21","author":"Sasako","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds106_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds106_bb0025","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s12032-009-9321-x","article-title":"Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer","volume":"27","author":"Choi","year":"2010","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mds106_bb0030","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","article-title":"Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study","volume":"10","author":"Boku","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds106_bb0035","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"Ajani","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds106_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4143\/crt.2005.37.2.79","article-title":"Chemotherapy for advanced gastric cancer: slow but further progress","volume":"37","author":"Kim","year":"2005","journal-title":"Cancer Res Treat"},{"key":"10.1093\/annonc\/mds106_bb0045","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","article-title":"Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study)","volume":"11","author":"Muro","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds106_bb0050","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2010.31.0326","article-title":"Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study","volume":"28","author":"Okamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds106_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/annonc\/mdm439","article-title":"A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer","volume":"19","author":"Kim","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds106_bb0060","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0161-6420(00)00640-0","article-title":"Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect","volume":"108","author":"Esmaeli","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1093\/annonc\/mds106_bb0065","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archopht.120.9.1180","article-title":"Docetaxel secretion in tears: association with lacrimal drainage obstruction","volume":"120","author":"Esmaeli","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1093\/annonc\/mds106_bb0070","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0161-6420(02)00989-2","article-title":"Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer","volume":"109","author":"Esmaeli","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1093\/annonc\/mds106_bb0075","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1200\/JCO.2005.04.4453","article-title":"Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel","volume":"24","author":"Esmaeli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds106_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/annonc\/mdp319","article-title":"A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis","volume":"21","author":"Leyssens","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds106_bb0085","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1592\/phco.26.6.853","article-title":"Docetaxel-associated epiphora","volume":"26","author":"Kintzel","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1093\/annonc\/mds106_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1034\/j.1600-0420.2000.078001110.x","article-title":"Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy","volume":"78","author":"Prasad","year":"2000","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1093\/annonc\/mds106_bb0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.IOP.0000066648.33513.3D","article-title":"Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil","volume":"19","author":"Eiseman","year":"2003","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1093\/annonc\/mds106_bb0100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ajo.2005.01.052","article-title":"Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1","volume":"140","author":"Esmaeli","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1093\/annonc\/mds106_bb0105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3341\/jkos.2010.51.6.890","article-title":"Two cases of lacrimal drainage obstruction associated with S-1 anticancer treatment","volume":"51","author":"Park","year":"2010","journal-title":"J Korean Ophthalmol Soc"},{"key":"10.1093\/annonc\/mds106_bb0110","first-page":"259","article-title":"Investigation of epiphora following S-1 therapy","volume":"38","author":"Kitamura","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1093\/annonc\/mds106_bb0115","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1538-7836.2009.03731.x","article-title":"The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer","volume":"8","author":"Lee","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1093\/annonc\/mds106_bb0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10120-011-0015-7","article-title":"Survival benefit of gastrectomy +\/- metastasectomy in patients with metastatic gastric cancer receiving chemotherapy","volume":"14","author":"Kim","year":"2011","journal-title":"Gastric Cancer"},{"key":"10.1093\/annonc\/mds106_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/PL00011681","article-title":"Japanese classification of gastric carcinoma\u20142nd English edition","volume":"1","author":"Japanese Gastric Cancer A","year":"1998","journal-title":"Gastric Cancer"},{"key":"10.1093\/annonc\/mds106_bb0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10120-011-0003-y","article-title":"Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification","volume":"14","author":"Iwasa","year":"2011","journal-title":"Gastric Cancer"},{"key":"10.1093\/annonc\/mds106_bb0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/IOP.0b013e318032e908","article-title":"Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel","volume":"23","author":"McCartney","year":"2007","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1093\/annonc\/mds106_bb0140","first-page":"14","article-title":"Epiphora in patients receiving systemic 5-fluorouracil therapy","volume":"33","author":"Hassan","year":"1998","journal-title":"Can J Ophthalmol"},{"key":"10.1093\/annonc\/mds106_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1445-5994.1979.tb04317.x","article-title":"Ocular side effects with 5-fluorouracil","volume":"9","author":"Christophidis","year":"1979","journal-title":"Aust N Z J Med"},{"key":"10.1093\/annonc\/mds106_bb0150","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/07357909009012068","article-title":"Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity","volume":"8","author":"Loprinzi","year":"1990","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mds106_bb0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10120-007-0422-y","article-title":"Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer","volume":"10","author":"Yamanaka","year":"2007","journal-title":"Gastric Cancer"},{"key":"10.1093\/annonc\/mds106_bb0160","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1349-7006.2008.00773.x","article-title":"CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1","volume":"99","author":"Fujita","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mds106_bb0165","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1349-7006.2007.00573.x","article-title":"Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy","volume":"98","author":"Kim","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mds106_bb0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.cad.0000203382.07114.0f","article-title":"Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1","volume":"17","author":"Tsuruoka","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mds106_bb0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-007-0415-x","article-title":"Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients","volume":"60","author":"Kochi","year":"2007","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/8\/2065\/317827\/mds106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:38:43Z","timestamp":1624441123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419381220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0923753419381220"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds106","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}